| Name | Title | Contact Details |
|---|
Skyhawk Therapeutics is a drug discovery and development company focused on revolutionizing disease treatment with small molecules that correct RNA expression.
Spero is a multi-asset, clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts dedicated to identifying, developing and commercializing novel treatments focused on unmet needs of patients with multidrug-resistant (MDR) bacterial infections. Spero`s lead product candidate, SPR994, is designed to be the first broad-spectrum oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. Spero also has a platform technology known as its Potentiator Platform that it believes will enable it to develop drugs that will expand the spectrum and potency of existing antibiotics, including formerly inactive antibiotics, against Gram-negative bacteria. Spero`s lead product candidates generated from its Potentiator Platform are two intravenous, or IV,-administered agents, SPR741 and SPR206, designed to treat MDR Gram-negative infections in the hospital setting. Spero is also advancing SPR720, its novel oral therapy product candidate designed for the treatment of pulmonary non-tuberculous mycobacterial infection.
At MicroGEM, we are transforming the landscape of DNA and RNA extraction. Come see how our single-tube extraction workflows can work for you!
We specialize in recruiting clinical research talent and understand the hiring objectives of our Medical Device, Biotechnology, and Pharmaceutical clients.
Novara Tesija Michela and Priehs is a Southfield, MI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.